About
AION Labs is a venture studio dedicated to building and investing in startups that leverage AI to revolutionize drug discovery and development. It is a unique partnership formed by AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, supported by the Israeli Innovation Authority.
By combining global pharmaceutical expertise with cutting-edge AI, AION Labs' unique venture studio model creates an optimal environment for startups by fostering cross-industry partnerships, funding opportunities, and offering unparalleled access to pharma R&D expertise and data.
In just three years, AION Labs has launched nine companies and built a proven venture-formation engine. The portfolio has executed multiple pilots with its founding pharma partners, as well as additional collaborations with other pharma and biotech organizations, generating meaningful scientific progress across the drug R&D value chain. The model has also attracted strong market validation, including multiple up-rounds, significant follow-on investment from leading global venture funds.
Portfolio
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is AION Labs' primary focus as an investor?
- AION Labs is a venture studio dedicated to building and investing in startups that leverage AI to revolutionize drug discovery and development. It focuses exclusively on the Health Tech & Life Sciences sector.
- When was AION Labs founded and what is its operational model?
- AION Labs was founded in 2021 and operates as a venture studio. It is a partnership formed by AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, supported by the Israeli Innovation Authority.
- How many companies has AION Labs launched since its inception?
- In just three years since its founding in 2021, AION Labs has launched nine companies.
- Can you name some notable portfolio companies of AION Labs and their funding details?
- AION Labs' portfolio includes Cassidy Bio, which raised $8 million in August 2024, and Promise Bio, which raised $8.3 million in December 2024. For a full portfolio, please refer to startupim data.
- Has AION Labs had any exits from its portfolio companies?
- Yes, AION Labs had an exit in January 2026 with the acquisition of CombinAble.AI by insitro. The acquisition amount was undisclosed.
- What is AION Labs' activity as a lead investor?
- AION Labs has acted as a lead investor for companies such as Cellyrix Therapeutics (December 2024), CombinAble.AI (March 2024), and DenovAI Biotech (February 2023).
- What stages of funding does AION Labs typically participate in?
- AION Labs typically participates in Pre-Seed and Seed funding rounds, with some investments also in Undisclosed stages.
- What is the typical investment amount range for AION Labs?
- AION Labs' investment range is between $0 and $1 million per round.